title: Optimal duration of antibiotic therapy in vertebral osteomyelitis.
abstract: OBJECTIVE
  To compare the risk of relapse of vertebral osteomyelitis (VO), according to the duration of antibiotic therapy (< or =6 weeks versus >6 weeks).
  
  
  METHODS
  We performed a 10-year retrospective study to assess the risk of VO relapse and to verify that this risk was not enhanced in patients who received 6 weeks of antibiotic therapy (Group 1) as compared with those who received a longer treatment (Group 2). VO was diagnosed based on clinical manifestations, magnetic resonance imaging and/or computed tomography findings, and isolation of a pyogenic organism in blood cultures and/or a discovertebral biopsy. Relapse was diagnosed based on isolation of the same organism in blood cultures and/or a discovertebral biopsy. Outcome was evaluated 6 months post-treatment and in December 2004.
  
  
  RESULTS
  Group 1 included 36 patients (mean age, 58 +/- 15 years) and Group 2 included 84 patients (mean age, 67 +/- 15 years) (P = 0.003). Clinical data and microorganisms were comparable in the 2 groups. In the first 6 months, 6 (5%) patients died (Group 1, n = 2; Group 2, n = 4), and 5 (4%) in Group 2 relapsed, 2 with recurrent VO and 3 with recurrent bacteremia. In 2004, 91 patients were evaluated (mean follow-up, 40.6 +/- 31 months): 77 (85%) were cured, 13 (14%) died (Group 1, n = 3; Group 2, n = 10), 1 had VO due to a different microorganism (Group 2), and no long-term relapses occurred.
  
  
  CONCLUSIONS
  Our results suggest that antibiotic therapy of VO could be safely shortened to 6 weeks without enhancing the risk of relapse.
authors.affiliation: Infectious Diseases Unit, CHU La Miletrie, Poitiers, France. f.roblot@chu-poitiers.fr
authors.forename: F
authors.initials: F
authors.lastname: Roblot
authors.forename: J M
authors.initials: JM
authors.lastname: Besnier
authors.forename: L
authors.initials: L
authors.lastname: Juhel
authors.forename: C
authors.initials: C
authors.lastname: Vidal
authors.forename: S
authors.initials: S
authors.lastname: Ragot
authors.forename: F
authors.initials: F
authors.lastname: Bastides
authors.forename: G
authors.initials: G
authors.lastname: Le Moal
authors.forename: C
authors.initials: C
authors.lastname: Godet
authors.forename: D
authors.initials: D
authors.lastname: Mulleman
authors.forename: I
authors.initials: I
authors.lastname: Azaïs
authors.forename: B
authors.initials: B
authors.lastname: Becq-Giraudon
authors.forename: P
authors.initials: P
authors.lastname: Choutet
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010019:Osteomyelitis / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D012008:Recurrence; D012189:Retrospective Studies; D013122:Spinal Diseases / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents